Skip to content Skip to main menu

Pipelines

Our Microbiome Determines balanced health

Cancer Immunotherapy

Paradigm Shift in Cancer Therapeutics

Therapeutic Method:

Cytotoxic Agents (~1990) →
Targeted Therapy (~2010) →
Cancer Immunotherapy (2010~)

Cancer Immunotherapeutic:

PD1 blockage → microbial
extracellular vesicles (EVs)

Next-Generation Cancer Immunotherapeutic: Microbial EVs

  1. 1. New immunological targets: Targeting NK/IFN-g and MDSC (myeloid-derived suppressor cell) rather than T cells.
  2. 2. Modulation of metabolic dysfunction : Aim to modulate aerobic glycolysis and arginine depletion that leads to immune evasion
  3. 3. No toxicity: Safe and natural substances
  4. 4. Reasonable cost: No need for antibodies
  5. 5. Synergy with current immunotherapy

Mechanism of Action (MoA)

  1. 1. Tumor Microenvironment
    MD Healthcare cancer immunotherapy drug candidate MDH-001 inhibits inflammation in normal cells while selectively inducing apoptosis in cancer cells via ER stress pathway augmentation in the tumor microenvironment.
  1. 2. Tumor Macroenvironment
    MD Healthcare cancer immunotherapy drug candidates such as MDH-203 induces cancer cell death, MDSC reduction, and ultimately immune homeostasis to treat cancer at the tumor macroenvironmental level.

Cancer Immunotherapy Pipeline

As of Aug. 2019

Central Nervous System (CNS) Disease

Brain Drug Delivery Issue

Due to the strength and high selectivity of the blood-brain barrier (BBB), it is very challenging to deliver therapeutic agent to the brain for the treatment of CNS diseases such as Alzheimer’s, autism, and depression.

Microbial EVs Migrate to the Brain

Brain delivery of MDH-204

Oral delivery of the nano-sized microbial EV drug candidate MDH-204 proved that microbial EVs can pass the BBB and migrate directly to the brain to act on CNS diseases such as Alzheimer's Disease (AD)

CNS Disease Pipeline Summary

As of Aug. 2019

Metabolic Disease

Mucin-degrading Bacteria

The mucin-degrading bacterium Akkermansia muciniphila has emerged recently as a new treatment for a wide variety of metabolic diseases including obesity and diabetes (ref). However, as A. muciniphila is an extremely anaerobic bacteria that cannot survive exposure to oxygen, it is very challenging to use the bacterium itself as a drug. Therefore, microbial EVs isolated from A. muciniphila can provide therapeutic effects without the issue of oxygen exposure its parent cell faces.

Novel Mechanism of Action (MoA)

AMPK phosphorylation of MDH-301

MD Healthcare’s mucin-degrading microbial EV drug candidate, MDH-301, has a therapeutic effect on obesity and diabetes through regulation of intestinal permeability and metabolic function via AMPK phosphorylation.

Metabolic Disease Pipeline Summary

As of Aug. 2019

Allergy & Respiratory Disease

Current Understanding of Disease Development

Susceptible genes and environmental factors cause immune dysfunction that can lead to chronic inflammation resulting in allergies, asthma, COPD, and lung cancer. Therefore, we are developing a microbial EV drug pipeline targeting immune modulation for the treatment of allergy and respiratory diseases

Novel Mechanism of Action (MoA)

Inflammatory Signal Disruption of MDH-101

Inflammatory agents in the airway cause neutrophilic inflammation that leads to alveolar destruction and fibrosis that precede emphysema and chronic obstructive pulmonary disease (COPD). Interaction of inhaled MDH-101 with airway epithelial cells leads to interference of this inflammatory signaling and symptom mitigation.

Allergy & Respiratory Disease Pipeline Summary

As of Aug. 2019